Athenex, a US-China Pharma, Lands $225 Million Investment

Athenex, a US-China oncology company, announced that New York State will invest $225 million to build a large manufacturing facility for the company in the western part of the state. Athenex agreed to contribute $1.6 billion over ten years in wages, materials and supplies. In October, Athenex and Chongqing, China struck a similar deal in which the municipal government will build two factories for the company. Athenex will make APIs for global markets and oncology drugs for China in the plants, and it will be responsible for equipping them. Also in 2015, Athenex acquired Comprehensive Drug Enterprises, which included a Hong Kong R&D operation and a manufacturing facility in the Fengdu district of Chongqing. More details.... Share this with colleagues: // //